Ollin Biosciences registers two Phase 3 trials of OLN324 for diabetic macular edema

Ollin Biosciences registered two identically designed Phase 3 trials of its investigational drug OLN324 for diabetic macular edema during the week.

• ATACAMA (NCT07841899) is a Phase 3, randomized, active comparator-controlled trial testing OLN324 as a treatment for patients with diabetic macular edema, sponsored by Ollin Biosciences.¹ The study is not yet recruiting, with an estimated start date of October 15, 2026¹ and plans to enroll 450 participants¹, comparing OLN324 against aflibercept as an active comparator.¹ The primary outcome is change in ETDRS BCVA eye chart letter score from Day 1 to Week 48.¹
• GOBI (NCT07842016) is a second Phase 3, randomized, active comparator-controlled trial of OLN324, also sponsored by Ollin Biosciences for diabetic macular edema.² It is likewise not yet recruiting, with an estimated start date of October 15, 2026², plans to enroll 450 participants², and compares OLN324 against aflibercept.² Its primary outcome is the same change in ETDRS BCVA eye chart letter score from Day 1 to Week 48.²